11 mayo 2015
Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become resistant to prior anti-EGFR therapies.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/Dtw-ZsIRiNo/150511091553.htm
